PURPOSE: To assess the additional functional vascular information and the relationship between perfusion measurements and glucose metabolism (SUVmax) obtained by including a perfusion CT study in a whole-body contrast-enhanced PET/CT protocol in primary lung cancer lesions. METHODS: Enrolled in this prospective study were 34 consecutive patients with a biopsy-proven diagnosis of lung cancer who were referred for contrast-enhanced PET/CT staging. This prospective study was approved by our institutional review board, and informed consent was obtained from all patients. Perfusion CT was performed with the following parameters: 80 kV, 200 mAs, 30 scans during intravenous injection of 50 ml contrast agent, flow rate 5 ml/s. Another bolus of contrast medium (3.5 ml/s, 80 ml, 60-s delay) was administered to ensure a full diagnostic contrast-enhanced CT scan for clinical staging. The perfusion CT data were used to calculate a range of tumour vascularity parameters (blood flow, blood volume and mean transit time), and tumour FDG uptake (SUVmax) was used as a metabolic indicator. Quantitative and functional parameters were compared and in relation to location, histology and tumour size. The nonparametric Kruskal-Wallis rank sum test was used for statistical analysis. RESULTS: A cut-off value of 3 cm was used according to the TNM classification to discriminate between T1 and T2 tumours (i.e. T1b vs. T2a). There were significant perfusion differences (lower blood volumes and higher mean transit time) between tumours with diameter >30 mm and tumours with diameter <30 mm (p < 0.05; blood volume 5.6 vs. 7.1 ml/100 g, mean transit time 8.6 vs. 3.9 s, respectively). Also there was a trend for blood flow to be lower in larger lesions (p < 0.053; blood flow 153.1 vs. 98.3 ml/100 g tissue/min). Significant inverse correlations (linear regression) were found between blood volume and SUVmax in tumours with diameter >30 mm in diameter. CONCLUSION: Perfusion CT combined with PET/CT is feasible technique that may provide additional functional information about vascularity and tumour aggressiveness as a result of lower perfusion and higher metabolism shown by larger lesions.
PURPOSE: To assess the additional functional vascular information and the relationship between perfusion measurements and glucose metabolism (SUVmax) obtained by including a perfusion CT study in a whole-body contrast-enhanced PET/CT protocol in primary lung cancer lesions. METHODS: Enrolled in this prospective study were 34 consecutive patients with a biopsy-proven diagnosis of lung cancer who were referred for contrast-enhanced PET/CT staging. This prospective study was approved by our institutional review board, and informed consent was obtained from all patients. Perfusion CT was performed with the following parameters: 80 kV, 200 mAs, 30 scans during intravenous injection of 50 ml contrast agent, flow rate 5 ml/s. Another bolus of contrast medium (3.5 ml/s, 80 ml, 60-s delay) was administered to ensure a full diagnostic contrast-enhanced CT scan for clinical staging. The perfusion CT data were used to calculate a range of tumour vascularity parameters (blood flow, blood volume and mean transit time), and tumour FDG uptake (SUVmax) was used as a metabolic indicator. Quantitative and functional parameters were compared and in relation to location, histology and tumour size. The nonparametric Kruskal-Wallis rank sum test was used for statistical analysis. RESULTS: A cut-off value of 3 cm was used according to the TNM classification to discriminate between T1 and T2 tumours (i.e. T1b vs. T2a). There were significant perfusion differences (lower blood volumes and higher mean transit time) between tumours with diameter >30 mm and tumours with diameter <30 mm (p < 0.05; blood volume 5.6 vs. 7.1 ml/100 g, mean transit time 8.6 vs. 3.9 s, respectively). Also there was a trend for blood flow to be lower in larger lesions (p < 0.053; blood flow 153.1 vs. 98.3 ml/100 g tissue/min). Significant inverse correlations (linear regression) were found between blood volume and SUVmax in tumours with diameter >30 mm in diameter. CONCLUSION: Perfusion CT combined with PET/CT is feasible technique that may provide additional functional information about vascularity and tumour aggressiveness as a result of lower perfusion and higher metabolism shown by larger lesions.
Authors: Dushyant V Sahani; Sanjeeva P Kalva; Leena M Hamberg; Peter F Hahn; Christopher G Willett; Sanjay Saini; Peter R Mueller; Ting-Yim Lee Journal: Radiology Date: 2005-03 Impact factor: 11.105
Authors: Quan Sing Ng; Vicky Goh; Ernst Klotz; Heinz Fichte; Michele I Saunders; Peter J Hoskin; Anwar R Padhani Journal: AJR Am J Roentgenol Date: 2006-10 Impact factor: 3.959
Authors: Seung Hyup Hyun; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Su Jin Lee; Young Seok Cho; Ji Young Lee; Kyung-Han Lee; Byung-Tae Kim Journal: Ann Surg Oncol Date: 2009-10-14 Impact factor: 5.344
Authors: Salvatore Cappabianca; Annamaria Porto; Mario Petrillo; Barbara Greco; Alfonso Reginelli; Francesco Ronza; Francesca Setola; Giovanni Rossi; Andrea Di Matteo; Roberto Muto; Maria Luisa De Rimini; Sergio Piccolo; Mara Catalano; Pietro Muto; Nicoletta De Rosa; Enrica Barra; Ilaria De Rosa; Francesca Antinolfi; Giuseppe Antinolfi; Mario Caputi; Luca Brunese; Roberto Grassi; Antonio Rotondo Journal: J Clin Pathol Date: 2010-12-17 Impact factor: 3.411
Authors: P Veit-Haibach; D De Ruysscher; W van Elmpt; M Das; Martin Hüllner; H Sharifi; K Zegers; B Reymen; P Lambin; J E Wildberger; E G C Troost Journal: Radiother Oncol Date: 2013-09-14 Impact factor: 6.280
Authors: Martin W Huellner; Timothy D Collen; Philipp Gut; Ralph Winterhalder; Chantal Pauli; Joachim Diebold; Burkhardt Seifert; Klaus Strobel; Patrick Veit-Haibach Journal: EJNMMI Res Date: 2014-01-22 Impact factor: 3.138